Generation of an adenovirus-parvovirus chimera with enhanced oncolytic potential

Journal of Virology

Volumn 86, Issue 19, 2012, Pages 10418-10431

  El Andaloussi, Nazim ^a   Bonifati, Serena ^a   Kaufmann, Johanna K ^a   Mailly, Laurent ^b,c   Daeffler, Laurent ^a   Deryckére, François ^b   Nettelbeck, Dirk M ^a   Rommelaere, Jean ^a   Marchini, Antonio ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTRUCTURAL PROTEIN 1; PROTEIN VP; TETRACYCLINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CHIMERA; CONTROLLED STUDY; CYTOTOXICITY; GENE REPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PARVOVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS GENOME; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; BASE SEQUENCE; CELL PROLIFERATION; CELL SURVIVAL; CLONING, MOLECULAR; FIBROBLASTS; GENE DELETION; HEK293 CELLS; HELA CELLS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; ONCOLYTIC VIRUSES; PARVOVIRUS; PROMOTER REGIONS, GENETIC; TETRAZOLIUM SALTS; THIAZOLES; VIROLOGY;

ADENOVIRIDAE; PARVOVIRUS; RODENTIA;

EID: 84869015084     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00848-12     Document Type: Article

References (36)

1. Allaume X, et al. 2012. Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid. J. Virol. 86:3452-3465.
2. Bewig B, Schmidt WE. 2000. Accelerated titering of adenoviruses. Biotechniques 28:870-873.
3. Bodendorf U, Cziepluch C, Jauniaux JC, Rommelaere J, Salome N. 1999. Nuclear export factor CRM1 interacts with nonstructural proteins NS2 from parvovirus minute virus of mice. J. Virol. 73:7769-7779.
4. Chartier C, et al. 1996. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. Virol. 70: 4805-4810.
5. Cornelis JJ, Deleu L, Kock U, Rommelaere J. 2006. Parvovirus oncosuppression, p 365-378. In Kerr JR, Cotmore SF, Bloom ME, Linden RM, Parrish CR (ed), Parvoviruses. Hodder Arnold, London, United Kingdom.
6. Cornelis JJ, Salome N, Dinsart C, Rommelaere J. 2004. Vectors based on autonomous parvoviruses: novel tools to treat cancer? J. Gene Med. 6(Suppl. 1):S193-S202.
7. Cotmore SF, Tattersall P. 2007. Parvoviral host range and cell entry mechanisms. Adv. Virus Res. 70:183-232.
8. Di Piazza M, et al. 2007. Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells. J. Virol. 81:4186-4198.
9. Edelstein ML, Abedi MR, Wixon J. 2007. Gene therapy clinical trials worldwide to 2007-an update. J. Gene Med. 9:833-842.
10. El-Andaloussi N, et al. 2011. Novel adenovirus-based helper system to support production of recombinant parvovirus. Cancer Gene Ther. 18: 240-249.
11. Everts M, Curiel DT. 2004. Transductional targeting of adenoviral cancer gene therapy. Curr. Gene Ther. 4:337-346.
12. Glasgow JN, Everts M, Curiel DT. 2006. Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther. 13:830-844.
13. Grekova S, et al. 2010. Activation of an antiviral response in normal but not transformed mouse cells: a new determinant of minute virus of mice oncotropism. J. Virol. 84:516-531.
14. Guan W, Wong S, Zhi N, Qiu J. 2009. The genome of human parvovirus b19 can replicate in nonpermissive cells with the help of adenovirus genes and produces infectious virus. J. Virol. 83:9541-9553.
15. Hillen W, Berens C. 1994. Mechanisms underlying expression of Tn10 encoded tetracycline resistance. Annu. Rev. Microbiol. 48:345-369.
16. Hristov G, et al. 2010. Through its nonstructural protein NS1, parvovirus H-1 induces apoptosis via accumulation of reactive oxygen species. J. Virol. 84:5909-5922.
17. Kestler J, et al. 1999. cis requirements for the efficient production of recombinant DNA vectors based on autonomous parvoviruses. Hum. Gene Ther. 10:1619-1632.
18. Lagrange M, et al. 2007. Intracellular scFvs against the viral E6 oncoprotein provoke apoptosis in human papillomavirus-positive cancer cells. Biochem. Biophys. Res. Commun. 361:487-492.
19. Langland JO, Cameron JM, Heck MC, Jancovich JK, Jacobs BL. 2006. Inhibition of PKR by RNA and DNA viruses. Virus Res. 119:100-110.
20. Mathis JM, Stoff-Khalili MA, Curiel DT. 2005. Oncolytic adenoviruses- selective retargeting to tumor cells. Oncogene 24:7775-7791.
21. Mittereder N, March KL, Trapnell BC. 1996. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70:7498-7509.
22. Nettelbeck DM. 2008. Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer. J. Mol. Med. (Berl). 86:363-377.
23. Nettelbeck DM, et al. 2004. Retargeting of adenoviral infection to melanoma: combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAA. Int. J. Cancer 108:136-145.
24. Nuesch JP. 2006. Regulation of the non-structural protein functions by differential synthesis, modification and trafficking. Edward Arnold Hodder Publishers Ltd., London, United Kingdom.
25. Nüesch JP, Lacroix J, Marchini A, Rommelaere J. 2012. Molecular pathways: rodent parvoviruses-mechanisms of oncolysis and prospects for clinical cancer treatment. Clin. Cancer Res. 18:3516-3523.
26. Ohshima T, et al. 1998. Induction of apoptosis in vitro and in vivo by H-1 parvovirus infection. J. Gen. Virol. 79(Pt 12):3067-3071.
27. Ran Z, Rayet B, Rommelaere J, Faisst S. 1999. Parvovirus H-1-induced cell death: influence of intracellular NAD consumption on the regulation of necrosis and apoptosis. Virus Res. 65:161-174.
28. Raykov Z, Legrand V, Homann HE, Rommelaere J. 2002. Transient suppression of transgene expression by means of antisense oligonucleotides: a method for the production of toxin-transducing recombinant viruses. Gene Ther. 9:358-362.
29. Rein DT, Breidenbach M, Curiel DT. 2006. Current developments in adenovirus-based cancer gene therapy. Future Oncol. 2:137-143.
30. Rohmer S, Mainka A, Knippertz I, Hesse A, Nettelbeck DM. 2008. Insulated hsp70B' promoter: stringent heat-inducible activity in replication- deficient, but not replication-competent adenoviruses. J. Gene Med. 10:340-354.
31. Rommelaere J, Cornelis JJ. 1991. Antineoplastic activity of parvoviruses. J. Virol. Methods 33:233-251.
32. Rommelaere J, et al. 2010. Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev. 21:185-195.
33. Russell WC. 2009. Adenoviruses: update on structure and function. J. Gen. Virol. 90:1-20.
34. Timpe JM, Verrill KC, Trempe JP. 2006. Effects of adeno-associated virus on adenovirus replication and gene expression during coinfection. J. Virol. 80:7807-7815.
35. Weitzman MD, Fisher KJ, Wilson JM. 1996. Recruitment of wild-type and recombinant adeno-associated virus into adenovirus replication centers. J. Virol. 70:1845-1854.
36. Yao F, et al. 1998. Tetracycline repressor, tetR, rather than the tetRmammalian cell transcription factor fusion derivatives, regulates inducible gene expression in mammalian cells. Hum. Gene Ther. 9:1939-1950.